MCI: CPAP Treatment of OSA

Kaitlin Berry
Thomas Jefferson University, kaitlin.berry@jefferson.edu

Cindy Cheng, MD, PhD
Thomas Jefferson University, Cynthia.Cheng@jefferson.edu

Karl Doghramji, MD
Thomas Jefferson University, karl.doghramji@jefferson.edu

Follow this and additional works at: https://jdc.jefferson.edu/si_ctr_2022_phase1

Part of the Sleep Medicine Commons, and the Translational Medical Research Commons

Let us know how access to this document benefits you

Recommended Citation
Berry, Kaitlin; Cheng, MD, PhD, Cindy; and Doghramji, MD, Karl, "MCI: CPAP Treatment of OSA" (2020). Phase 1. Paper 95.
https://jdc.jefferson.edu/si_ctr_2022_phase1/95

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
MCI: CPAP Treatment of OSA
Kaitlin Berry BS, Cynthia Cheng, MD, PhD*, Karl Doghramji MD

Introduction: An estimated 30 percent of adults (20% of men and 10% of women) in the US have sleep apnea. Approximately 60% of patients with Mild Cognitive Impairment (MCI) are also diagnosed with Obstructive Sleep Apnea (OSA). The suggested mechanism of this is damage to the brain due to hypoxia during sleep. Few studies have investigated the effect of Continuous Positive Airway Pressure (CPAP) treatment for OSA, on mild cognitive impairment.

Methods: Patients are screened for eligibility based on specific inclusion and exclusion criteria. Potentially eligible patients who screen positive for MCI using the Telephone Interview for Cognitive Status (TICS) survey are enrolled. CPAP adherent (n=200), CPAP non-adherent (n=160), and no apnea control (n=100) groups are followed for 1 year total with study visits at zero and six months that include cognitive testing and brain MRI.

Results: At Jefferson, 272 charts have been reviewed, with 2 patients enrolled in the study. Across all study sites, approximately 5000 charts have been reviewed, and 157 patients enrolled. We hypothesize that adherence with CPAP treatment of OSA will delay the progression of cognitive impairment.

Discussion: MCI is a precursor to Alzheimers, for which there is currently no effective treatment. If CPAP proves to be effective in delaying the progression of cognitive impairment in patients with OSA and MCI, CPAP may have a clinically significant impact on patient morbidity, mortality, and quality of life.